Safracins, new antitumor antibiotics. III. Biological activity.
Safracins A and B have antibacterial activity against Gram-positive and Gram-negative bacteria in vitro but no therapeutic activity in mice infected with Staphylococcus aureus. Safracins A and B induce abnormal morphological changes in Echerichia coli cells. Tests with transplantable mice tumors demonstrate that safracins A and B inhibit the growth of P388 leukemia and IMC carcinoma.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D002277:Carcinoma / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D007546:Isoquinolines / Q000627:therapeutic use / Q000633:toxicity; D007941:Leukemia P388 / Q000188:drug therapy; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D013045:Species Specificity
D000903:Antibiotics, Antineoplastic; D007546:Isoquinolines; C039866:safracin A; C039865:safracin B